Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Invested Capital (2019 - 2025)

Historic Return on Invested Capital for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to 0.13%.

  • Neurocrine Biosciences' Return on Invested Capital fell 200.0% to 0.13% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.13%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.14% for FY2025, which is 200.0% down from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Return on Invested Capital is 0.13%, which was down 200.0% from 0.13% recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Return on Invested Capital ranged from a high of 0.16% in Q3 2024 and a low of 0.03% during Q1 2023
  • Its 4-year average for Return on Invested Capital is 0.11%, with a median of 0.13% in 2025.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first crashed by -1200bps in 2021, then skyrocketed by 1300bps in 2024.
  • Over the past 4 years, Neurocrine Biosciences' Return on Invested Capital (Quarter) stood at 0.05% in 2021, then soared by 69bps to 0.08% in 2023, then soared by 83bps to 0.15% in 2024, then decreased by -11bps to 0.13% in 2025.
  • Its Return on Invested Capital was 0.13% in Q4 2025, compared to 0.13% in Q3 2025 and 0.13% in Q2 2025.